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SAMHD1 is recurrently mutated in T-cell
prolymphocytic leukemia
Patricia Johansson1,2, Ludger Klein-Hitpass2, Axel Choidas3, Peter Habenberger3, Bijan Mahboubi4, Baek Kim4,
Anke Bergmann5, René Scholtysik2, Martina Brauser2, Anna Lollies2, Reiner Siebert5,6, Thorsten Zenz7,8, Ulrich Dührsen1,
Ralf Küppers2,8 and Jan Dürig1,8
Abstract
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy with a median survival of the patients of less than
two years. Besides characteristic chromosomal translocations, frequent mutations affect the ATM gene, JAK/STAT
pathway members, and epigenetic regulators. We here performed a targeted mutation analysis for 40 genes selected
from a RNA sequencing of 10 T-PLL in a collection of 28 T-PLL, and an exome analysis of ﬁve further cases.
Nonsynonymous mutations were identiﬁed in 30 of the 40 genes, 18 being recurrently mutated. We identiﬁed
recurrently mutated genes previously unknown to be mutated in T-PLL, which are SAMHD1, HERC1, HERC2, PRDM2,
PARP10, PTPRC, and FOXP1. SAMHD1 regulates cellular deoxynucleotide levels and acts as a potential tumor suppressor
in other leukemias. We observed destructive mutations in 18% of cases as well as deletions in two further cases. Taken
together, we identiﬁed additional genes involved in JAK/STAT signaling (PTPRC), epigenetic regulation (PRDM2), or
DNA damage repair (SAMHD1, PARP10, HERC1, and HERC2) as being recurrently mutated in T-PLL. Thus, our study
considerably extends the picture of pathways involved in molecular pathogenesis of T-PLL and identiﬁes the tumor
suppressor gene SAMHD1 with ~20% of T-PLL affected by destructive lesions likely as major player in T-PLL
pathogenesis.
Introduction
T-cell prolymphocytic leukemia (T-PLL) is a rare leu-
kemia with an aggressive disease course and a median
survival of the patients of less than 2 years. Leukemic cells
are characterized by expression of pan-T-cell markers
with the unique feature of CD4 and CD8 co-expression in
25% of cases. A CD4+CD8− phenotype is observed in 60%
of patients, whereas a CD4−CD8+ phenotype is rare
(~15%)1,2. Most T-PLL carry typical genetic alterations,
namely inv(14)(q11q32), t(14;14)(q11;q32), or, less often, t
(X;14)(q28;q11). These alterations, involving the TCRAD
locus on chromosome 14q11, cause overexpression of the
oncogenes TCL1A on chromosome 14q32 or MTCP1 on
chromosome Xq283–6. Other frequent genetic lesions
involve chromosome 8 (idic(8p), t(8;8)(p21;q11), trisomy
8q), and the ATM gene on chromosome 11 (11q2.23).
ATM is deleted or mutated in up to 70% of cases7–9.
Further recurrent deletions or losses occur on chromo-
somes 12p13 (CDKN1B), 6q, 17p13.1 (TP53 locus), and
22q10. Sequencing analyses identiﬁed recurrent mutations
in members of the JAK/STAT signaling pathway, as well
as in epigenetic regulators7,11–14. Recent next-generation
sequencing studies included whole-genome and exome
sequencing7 as well as targeted deep sequencing13,14.
We characterized T-PLL by RNA sequencing, targeted
capture sequencing, and whole-exome sequencing (WES)
for somatic mutations, and by single-nucleotide poly-
morphism (SNP) arrays for detection of genomic imbal-
ances in candidate regions. We identiﬁed recurrent
mutations in SAMHD1 in 6/33 cases (18%). Copy number
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losses were observed in two more patients. Other genes
that exhibited recurrent mutations and/or copy number
alterations were HERC2, HERC1, PRDM2, PARP10,
PTPRC, and FOXP1.
Materials and methods
Patients and samples
Patient samples were obtained from archived material of
the participating institutions. Patients were diagnosed
between 2005 and 2012 in accordance with the WHO
2008 classiﬁcation2. The study was approved by the
ethical review committees of the Universities of Duisburg-
Essen and Kiel (14-6080-BO and B295/11). All patients
provided written informed consents according to the
Declaration of Helsinki. The detection of an inv(14)/t
(14;14) or t(X;14) by cytogenetic analysis and/or detection
of TCL1 or MTCP1 breakpoints by FISH was required for
inclusion into the study. Clinical data of 33 study patients
are summarized in Table 1. Standard clinical criteria were
applied for initiation of therapy15. RNA sequencing data
and copy number analyses were assessed for 10 patients.
As control, we sequenced T-cell RNA from ﬁve healthy
donors. CD3+ T cells were enriched by magnetic cell
separation (Miltenyi Biotech, Bergisch Gladbach). For
28 samples, including the 10 with RNA-sequencing ana-
lysis, DNA capture sequencing was performed. WES was
carried out for ﬁve additional T-PLL. The assignment of
samples and experiments is given in Supplementary Table
1.
Tumor cell enrichment
Details are given in the supplementary methods.
RNA and DNA isolation
RNA and DNA were extracted from 1–2× 107 enriched
tumor cells per sample. Details are given in the supple-
mentary methods.
Transcriptome sequencing
Sample libraries were prepared from RNA of isolated
cells of 10 patients and ﬁve healthy blood donors. RNA
sequencing (RNA-Seq) was performed on the HiSeq
2500 system with 2× 101 bp paired-end reads (Illumina).
Duplicate reads were removed and reads were quality
ﬁltered. Mutations were considered only if the particular
position was covered at least 20-fold. For exclusion of
polymorphisms, the dbSNP database was used. In general,
single nucleotide variants were excluded if they matched
i) a 1000 genomes entry and/or ii) exhibited an annotated
variant allele frequency (VAF) above 1% and/or iii)
occurred in one or more healthy donor samples. Filtering
against healthy donor samples was performed to exclude
sequencing artefacts. Database version dbSNP137 was
used for data evaluation. Expression analysis of RNA-Seq
data was performed with Partek Genomics Suite software,
version 6.6; 2016 (Partek Inc., St. Louis, MO, USA)16.
Further details are given in the supplementary methods.
Data are available under GEO accession number
GSE100882.
Targeted capture sequencing
To validate candidate mutations in genes identiﬁed by
RNA-Seq, we selected 40 genes for which capture oligo-
nucleotides for all coding exons of the respective genes
were designed (Fig. 1). Further information is given in the
supplementary methods. All variant calls originating from
positions covered with less than 20 reads were removed.
We excluded variants with less than 20% VAF and ana-
lyzed non-synonymous variants only. Polymorphisms
were excluded as indicated above. Database version
dbSNP137 was used for evaluation of capture sequencing
data. Data are available under SRA accession number
SRP111041.
Whole-exome sequencing
For ﬁve T-PLL samples WES was performed. SNPs with
entries in the 1000 genomes project17 were removed. We
eliminated mutations if the respective position was cov-
ered with less than 20 reads. Only non-synonymous
mutations were considered. We excluded variants with a
VAF below 20%. Database version dbSNP147 was used for
data evaluation. Data are available under SRA accession
number SRP111041.
Ampliﬁcation and sequence analysis of mutations
To verify candidate mutations detected in SAMHD1 by
targeted capture sequencing or WES, we selected the
respective mutated positions in this gene for three
SAMHD1-mutated T-PLL. For all three cases, non-tumor
DNA extracted from CD14+ and CD19+ cells was avail-
able. After PCR, amplicons were analyzed by Sanger
sequencing (ABI3130 Genetic Analyzer; Applied Biosys-
tems, Life Technologies). Primer sequences are available
from the authors upon request.
Copy number analysis
Copy number variation (CNV) analysis was carried out
on Affymetrix SNP 6.0 microarrays (n= 10) and CytoScan
HD arrays (n= 4; Affymetrix, Santa Clara, CA, USA).
Further details are given in the supplementary
information.
Western blotting
For analysis of SAMHD1, equal amounts of protein
lysates were separated by SDS-PAGE and transferred to a
nitrocellulose membrane. Details are found in the sup-
plementary information.
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Quantitative reverse transcription PCR
RNA was transcribed into cDNA with the high-capacity
cDNA reverse transcription kit (Applied Biosystems).
Details are given in the supplementary methods.
Cell viability assay
For determination of the number of metabolically active
cells, the CellTiter-Glo LuminescenT-cell Viability Assay
(Promega, Fitchburg, WI, USA), which is based on
quantiﬁcation of ATP, was used. Details are described in
the supplementary methods.
Determination of cellular dNTP content
To obtain intracellular dNTPs, cell pellets prepared
from 2× 106 cells of seven T-PLL samples comprising
four SAMHD1 mutated and three wild-type samples as
well as three CD3+ MACS-enriched healthy donor sam-
ples were lysed. The extraction and quantitative mea-
surement of intracellular dNTPs were conducted as
reported previously18.
Results
Identiﬁcation of mutations in T-PLL by RNA and DNA
sequencing
Outline of the experimental design
For identiﬁcation of recurrent mutations in T-PLL, we
ﬁrst performed RNA-Seq analysis of isolated tumor cells
of 10 cases. We then selected 40 candidate genes from this
analysis and studied them for somatic mutations in an
extended cohort of 28 patients with a targeted DNA
capture sequencing approach. Five additional T-PLL were
analyzed by WES. For both DNA-sequencing analyses, we
excluded mutations with low coverage (read counts < 20)
at a respective position and occurring only at subclonal
levels, as mutation detection is less reliable in these
instances. The cutoff for subclonality was set to 20%.
Polymorphisms were excluded (see Materials and Meth-
ods section).
Transcriptome sequencing
In the RNA-Seq analysis of 10 T-PLL, we obtained an
average number of 9.5 million reads on the target region
after quality ﬁltering and duplicate removal. Focusing on
variants with high sequence quality scores, we selected all
genes carrying non-synonymous mutations and fulﬁlling
the following criteria: (i) mutations in a gene in at least
two T-PLL and (ii) a quality score of 1000, which is the
highest possible value. The score is calculated as the
−10log10 of the p value given by the AVADIS software.
The 40 genes fulﬁlling the criteria (Fig. 1) were subjected
to further analyses on the DNA level.
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Capture sequencing
All coding exons of the 40 candidate genes selected
from the RNA-Seq analysis were studied by a targeted
deep sequencing approach in a total of 28 T-PLL,
including the 10 samples on which RNA-Seq was per-
formed. The average sequence coverage for the target
region in the capture approach was 151, with 97% of
target-region nucleotides covered at least 20 times.
Twenty-nine of the forty genes (73%) showed non-
synonymous mutations (Fig. 1). Most mutations
appeared with VAF of 40–60%, indicating that they are
clonal heterozygous mutations (Fig. 2; but note that SNVs
with VAF below 20% were ﬁltered out). Two genes (ATM
and SAMHD1) showed several mutations with VAF
between 90 and 100%, suggesting either homozygous or
hemizygous clonal mutations. Ten of the forty genes
selected from the RNA-Seq analysis were not found to be
mutated in the targeted sequencing (and also not in a
WES of ﬁve further cases, see below). The discrepancy to
the RNA-Seq data is mainly due to the fact that we
applied more stringent selection criteria in the DNA
analysis (e.g., VAF ≥ 20%). Moreover, not all mutations
identiﬁed by RNA-Seq were validated in the targeted
sequencing approach, indicating some false-positive
results in the RNA-Seq analysis, or that some alleles
with subclonal mutations were preferentially transcribed.
WES
Five further T-PLL were analyzed by WES. On average,
the target region of the exome was covered 75 times
across all samples. Overall 88% of nucleotides were cov-
ered at least 20 times. After applying the above-
mentioned ﬁltering criteria, we ﬁrst focused on the 40
genes selected for targeted sequencing. Ten of the forty
genes (25%), namely ATM, FOXP1, HERC1, HERC2,
JAK3, NOTCH1, PARP10, PRMT2, SAMHD1, and
STAT5B, showed non-synonymous mutations (Fig. 1).
Analyzing the complete WES data, we identiﬁed several
previously unreported recurrently mutated genes (Sup-
plementary Table 2). Three T-PLL displayed mutations in
the ryanodine receptor 3 gene, RYR3, namely two repla-
cement mutations and one splice site mutation. RYR3 can
release calcium from the endoplasmic reticulum. PARN
was mutated in two T-PLL. It encodes a poly(A)-speciﬁc
ribonuclease, which degrades poly(A) tails of mRNAs.
PCLO, coding for the piccolo presynaptic cytomatrix
protein, was mutated in two T-PLL. This gene is also
frequently mutated in diffuse large B-cell lymphomas19,20.
One T-PLL also carried a mutation in the IL2RG gene,
which is known to be recurrently mutated in T-PLL7.
Combining capture (n= 28) and WES data (n= 5), we
observed in total mutations in 30 of the 40 genes (75%).
ATM was the most frequently mutated gene, with 76% of
cases harboring ATM mutations (Fig. 1), in line with prior
studies9. Other genes known to be mutated in T-PLL7,13,14
were also recurrently mutated in our cohort, including
JAK3 (27% of cases mutated) and STAT5B (12%). Muta-
tions in genes encoding epigenetic regulators, including
four members of the KMT2 lysine-methyltransferase
family, were observed in 3–9% of cases, and overall in 6
of the 33 cases. Mutations in other epigenetic regulators
occurred at lower frequencies compared to previous
reports, e.g., BCOR and TET2 each in only 3% of cases
(Fig. 1), whereas in prior studies, they were mutated in up
to 9% and up to 17% of T-PLL, respectively7,13,14.
We also identiﬁed recurrently mutated genes known to
be involved in tumorigenesis of various hematologic
malignancies, but which have not been described in T-
PLL yet. These are SAMHD1, HERC1, HERC2, PRDM2,
PARP10, PTPRC, and FOXP1, which could be assigned to
distinct functional categories (Fig. 1).
Besides ATM, the group of mutated genes related to
DNA damage/repair included SAMHD1 as the second
most frequently mutated gene, which was mutated in 18%
of cases. The pattern and distribution of these mutations
are depicted in Figs. 1 and 3. SAMHD1 encodes a dGTP-
activated triphosphohydrolase, which regulates the cel-
lular dNTP pool. Inactivating mutations in SAMHD1,
which lead to increased dNTP levels, promote tumor cell
survival. In our cohort, the majority of SAMHD1 muta-
tions are frameshift or nonsense mutations. Three of six
mutated cases with four SAMHD1 mutations could be
used for veriﬁcation studies by PCR and Sanger sequen-
cing. All SAMHD1 mutations observed in the next-
generation sequencing approaches were conﬁrmed. The
pattern and distribution of these mutations are depicted
in Fig. 3. An analysis of corresponding non-tumor DNA of
these patients conﬁrmed the somatic origin of three of the
four mutations, whereas in the patient with two SNVs in
the gene one of these was also detected in the non-tumor
DNA, indicating that this is a germline variant. To test for
mutual exclusivity of SAMHD1 mutations with other
recurrent mutations, we performed a contingency analy-
sis, which revealed a signiﬁcant negative association
between ATM and SAMHD1 mutations (Fisher’s exact
test, p= 0.02).
The genes HERC2 and HERC1, which are mutated in 12
and 9% of T-PLL, respectively, encode for E3 ubiquitin
protein ligases. In both genes, we observed replacement
mutations distributed along the whole length of the gene.
HERC2 and HERC1 function as DNA repair genes21.
HERC1 is recurrently mutated in T-cell acute lympho-
blastic leukemias (T-ALL)22.
PARP10, encoding the mono-ADP-ribosyltransferase
PARP10, is mutated in 3/33 cases (9%). Two mutations
lead most likely to loss of the protein or impaired protein
function as they are a nonsense mutation and a missense
mutation in the ubiquitin-interacting motif, which is part
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of the catalytic domain of the protein23. PARP10 is
recruited to stalled replication forks and mediates cellular
resistance to DNA damage, thereby promoting genomic
stability24.
The most frequently mutated gene in the group of
epigenetic regulators is PRDM2, with 12% of T-PLL
harboring mutations. It is a member of a nuclear histone/
protein methyltransferase superfamily and described as
tumor suppressor gene, mutated in several types of can-
cers25,26. Microsatellite-instable tumors show frequent
frameshift mutations of PRDM227. Three of four muta-
tions are predicted to change the amino-acid sequence in
the coiled-coil domain of the protein. The lysine-
methyltransferase genes KMT2B and KMT2E are muta-
ted in three cases each (9%). All mutations are missense
mutations, dispersed along the gene. KMT2B, mutated in
several cancers28, is a methyltransferase, while KMT2E,
which was initially grouped to the KMT2 family and is
also mutated in various cancers29, seems to lack intrinsic
histone methyltransferase activity.
PTPRC, encoding CD45, is expressed on all human
hematopoietic cells, and has, among other functions, a
role in inhibiting JAK/STAT signaling. A downregulation
of CD45 is reported in T-ALL carrying PTPRC muta-
tions30. We observed replacement mutations in PTPRC in
9% of cases. Two of three mutations were located in the
catalytic protein tyrosine phosphatase domain. CD45
protein expression measured by FACS was slightly
reduced in two of the three mutated cases (not shown).
Finally, 9% of T-PLL in our cohort carried mutations in
FOXP1, encoding a ubiquitously expressed transcription
factor and essential regulator in human CD4+ T cells31,32.
All mutations, including missense and nonsense muta-
tions, are located in the forkhead domain, which mediates
monomeric DNA binding33.
Copy number variations
To identify gains and losses in this T-PLL cohort, we
performed genome-wide CNV analyses for 14 patients
(Table 2). Besides already known CNV, we identiﬁed
several previously unknown gains and losses as well as
uniparental disomies (UPDs) for the 40 genes of interest
(Table 2). Two of fourteen (14%) patients displayed losses
of the SAMHD1 locus at 20q11. In addition, we identiﬁed
two further patients carrying UPDs involving SAMHD1.
None of these four patients had a point mutation or small
indel in SAMHD1. For HERC2, HERC1, FOXP1, and
PRDM2, no copy number alterations were observed.
In the region containing PTPRC, UPDs were observed
in 3/14 patients (21%). None of these patients displayed
Fig. 1 Distribution of mutated genes in the T-PLL cohort analyzed by targeted capture sequencing and WES. Mutated genes are indicated as
black ﬁelds for the 33 T-PLL that carried at least one mutated gene. * indicate the ﬁve cases for which results are generated by WES. Not listed are 10
genes without any mutations, which are BCL11B, CBL, CUX1, ETV6, JAK1, MTOR, RUNX1, SUZ12, VOPP1, and ZRSR2
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other PTPRC mutations. Recurrent gains were observed
in BCL11B in 4/14 patients (29%). The role of BCL11B,
which is a main maturation factor of T cells34,35, in
hematologic malignancies is still discussed. In T-ALL it is
reported as either a tumor suppressor or oncogene36,37.
SAMHD1 protein expression is reduced in T-PLL carrying
mutations or gene losses
As most mutations in SAMHD1 were destructive or
caused loss of one allele, we analyzed whether these
genetic lesions affected RNA and/or protein expression of
SAMHD1. Quantitative real-time reverse transcription
PCR showed variable mRNA levels of SAMHD1 in nine
T-PLL analyzed (Fig. 4a). Three T-PLL with SAMHD1
point mutations or a deletion were among the ﬁve T-PLL
with lowest transcript levels. However, there was no strict
correlation between SAMHD1 mRNA levels and presence
of mutations. More importantly, western blot analysis of
12 T-PLL revealed that T-PLL without genetic lesions in
SAMHD1 had strong protein expression, comparable to
normal peripheral blood CD4+ and CD8+ T cells,
whereas three of the four mutated cases had hardly
detectable levels, and one case slightly reduced levels (Fig.
4b). A similarly low expression was observed for cases
with losses and even for one case with a UPD (Fig. 4b).
T-PLL cells carrying SAMHD1 mutations do not respond
differently to cytarabine in vitro
SAMHD1 reduces cytarabine (Ara-C) toxicity in acute
myeloid leukemia cells38. Ara-CTP, which is the active
triphosphate metabolite of Ara-C, is hydrolyzed by
SAMHD1 as its direct substrate, which results in reduc-
tion of Ara-C levels. Hence, in cells with inactive
SAMHD1, the cytotoxic activity of Ara-C is potentiated38.
On the other hand, SAMHD1 may potentially also
decrease cell sensitivity to AraC, namely due to the
increase of cellular dCTP as competitor of AraCTP. The
net outcome may depend on cell types. Although Ara-C is
not particularly effective in T-PLL39, we tested drug
toxicity to determine a potential effect of Ara-C in cases
with SAMHD1 mutations. We performed cell viability
assays on thawed viably cryopreserved T-PLL cells after
treatment with Ara-C and a number of other cytotoxic
agents in different concentrations (Table 3). However, we
observed no difference in the IC50 values between cells
with low or high SAMHD1 protein expression, indicating
that Ara-C is not cytotoxic for T-PLL cells, even not in
those with low SAMHD1 expression (Fig. 5). The
response of SAMHD1 mutant cases was not improved for
any of the drugs tested. When analyzing the cases for the
ﬁve most frequent mutations occurring in this cohort, we
observed next to Ara-C non-responsiveness that
SAMHD1 mutant cases neither responded to ﬂudarabine
nor clofarabine. By contrast, four of the ATM mutated
cases responded well to ﬂudarabine and clofarabine
(Table 3). Each of the four cases carried non-synonymous
mutations that were predicted to be destructive for ATM
protein function by at least 5/7 prediction tools. Two of
the cases additionally showed deletions of the second
ATM allele. Hence, although the functional impairment of
ATM in these cases could not be experimentally
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validated, it seems that in these T-PLL, ATM mutations
are not linked to resistance against ﬂudarabine or
clofarabine.
Correlating SAMHD1 mutations to clinical data, we
observed no differences between mutated and unmutated
cases in terms of age at diagnosis, genetic group, T-PLL
immunophenotype, absolute white blood cell count, and
absolute lymphocyte count at diagnosis, sites of involve-
ment or response to therapy (Table 1).
Intracellular dNTP levels of SAMHD1-mutated T-PLL are
elevated compared to SAMHD1 wild-type and healthy
blood donor-derived CD3+ samples
Intracellular dNTP levels measured from 2× 106 cells
of four SAMHD1-mutated samples revealed detectable
levels, whereas no dNTPs were detected in three T-PLL
SAMHD1 wild-type samples and three healthy donor-
derived CD3+ samples, using the same cell numbers for
analysis (Fig. 6). The dNTP levels did not correlate with
the size of the SAMHD1 mutant clone. The contingency
analysis revealed a signiﬁcant difference between
SAMHD1-mutated and unmutated samples (p= 0.0048,
two-tailed Fisher’s exact test).
Discussion
T-PLL is characterized by inversions or translocations
involving the TCL1 gene or the MTCP1 gene, along with
one of the TCR loci3–6. Further genetic lesions involved in
T-PLL pathogenesis involve ATM7–9, members of the
JAK/STAT signaling pathway, and epigenetic
regulators7,11,12,40.
We focused here on 40 candidate genes selected from
an exploratory RNA-Seq analysis. Formally, we cannot
exclude that a few alterations identiﬁed in the RNA or
DNA analyses are not somatic mutations but represent
germline variants, because for most cases non-tumor
RNA or DNA was not available. However, our stringent
ﬁltering against known polymorphisms, the occurrence of
distinct non-synonymous mutations for recurrently
mutated genes, and the direct experimental veriﬁcation
for the somatic origin of three of four tested SAMHD1
mutations together argue that the vast majority of events
described here are indeed somatic mutations. Overall, our
results conﬁrm previously reported data from our12 and
other groups7 and furthermore reveal novel recurrently
altered genes in T-PLL (Fig. 1).
Most recurrently altered genes encode proteins with
functions in DNA damage/repair. This category included
HERC2 and HERC1, the latter of which has been pre-
viously reported as recurrently mutated in up to 13% of
patients with T-ALL22. We observed nonsense and mis-
sense mutations in the ubiquitin-interacting motif of
PARP10. As PARP10 deﬁciency leads to severe DNA
repair defects41, these mutations may disturb DNA repair
in T-PLL. Ten of fourteen patients (71%) displayed gains
involving the PARP10 gene. Such gains are in a con-
siderable number of cases occurring due to formation of
an isochromosome i(8q). While the point mutations
observed in PARP10 likely have functional consequences,
it remains unclear whether these gains translate into
higher protein levels and hence functional alterations.
A further gene in the category of DNA damage/repair is
SAMHD1, which is mutated in 6/33 (18%) of cases and,
moreover, is affected by deletions in two further cases.
SAMHD1 encodes a dGTP-activated tripho-
sphohydrolase, which regulates the cellular dNTP pool42.
Inactivating mutations in SAMHD1 can promote tumor
cell survival as they lead to increased dNTP levels42.
SAMHD1 is recurrently mutated in CLL, and the protein
is supposed to act as a tumor suppressor43. Most muta-
tions we observed in SAMHD1 are frameshift or nonsense
mutations. In several cases, the high VAF of mutations
indicates biallelic destruction of the gene. SAMHD1 is
highly expressed in monocytes, macrophages, dendritic
cells, and resting T cells44,45. In T-PLL, we observed
variable SAMHD1 protein expression levels, but in gen-
eral protein expression of wild-type SAMHD1 was com-
parable to resting normal CD4+ and CD8+ T cells (Fig.
Fig. 3 Pattern and distribution of mutations in SAMHD1. Depicted are all mutations. The missense mutation in brackets was also observed in
hematopoietic non-tumor cells of a female patient carrying two SAMHD1 mutations. The scale indicates the numbering of the amino acids. SAM
sterile alpha motif, HDc Histidine (H)-Aspartate (D) containing
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4b). By contrast, T-PLL cases carrying SAMHD1 muta-
tions or losses showed hardly any SAMHD1 protein,
further validating the destructive nature of the mutations
(Fig. 4b). We also observed downregulation of SAMHD1
protein in four T-PLL cases not carrying mutations or
losses in the coding region of this gene (data not shown).
In these cases, epigenetic silencing might occur, although
at the group level we did not observe hypermethylation of
the SAMHD1 promotor by comparing over 50 T-PLL to
normal T-cell subsets (data not shown; to be published
elsewhere). Thus, the situation in T-PLL is different from
that of CD4 T cells of patients with Sézary syndrome in
which the SAMHD1 promotor is hypermethylated46,47.
We did not observe a stringent correlation between
SAMHD1 protein and mRNA expression (Fig. 4a), which
hints toward a regulation of gene expression on different
levels. Notably, in the present cohort SAMHD1 mutations
are signiﬁcantly negatively associated with ATM muta-
tions (Fisher’s exact test, p= 0.02). Hence, SAMHD1
inactivation may be an alternative lesion to loss of ATM
function to impede proper DNA repair in T-PLL cells.
The observation that SAMHD1 mutant cases did not
show differences to wild-type cases regarding clinical data
might be explained by the relatively low number of cases
analyzed, but even more by the aggressive nature of T-
PLL and short survival of patients with this disease, so
that moderate alterations of tumor cell physiology do not
translate into a signiﬁcant change of clinical outcome.
SAMHD1 regulates dNTP homeostasis by decreasing
intracellular dNTP levels. In T-PLL, we observed elevated
dNTP levels in SAMHD1-mutated cases compared to
SAMHD1 wild-type cases and CD3+ T cells from healthy
donors, conﬁrming that mutant SAMHD1 is not able to
regulate dNTP levels in T-PLL (Fig. 6). Nucleoside ana-
logs, which are used as therapeutic agents against leuke-
mias, are incorporated into the DNA by a competitive
mechanism. It was supposed that in leukemias SAMHD1
mutations causing loss of the proteins’ tumor-suppressive
function could lead to enhanced drug efﬁcacy48,49. How-
ever, for patients with acute myeloid leukemia it was
observed that Ara-CTP, the active metabolite of cytar-
abine, is a direct substrate of SAMHD1. Hence, intact
SAMHD1 reduces Ara-C levels, whereas impaired
SAMHD1 protein leads to more effective drug
responses38.
Although Ara-C is not generally effective in T-PLL, we
analyzed whether T-PLL with SAMHD1 mutations or
deletions show an increased sensitivity toward cytarabine.
However, this was not observed (Fig. 5). Testing of further
nucleoside analogs including Fludarabine and other drugs
showing cytotoxic effects in T-PLL also revealed no
increased sensitivity in SAMHD1mutant cases toward any
of the drugs (Table 3). Therefore, we conclude that the
disturbance of the dNTP pool caused by SAMHD1Ta
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mutations in T-PLL leads to a beneﬁt for the tumor cells,
since increased intracellular dNTPs promote cell cycle
progression, proliferation, and survival of the cells.
Regarding the non-responsiveness to drugs, in T-PLL
further regulatory mechanisms are likely playing a major
role in this context, reﬂecting the overall drug resistance
of these tumor cells.
In the present cohort, PRDM2 is the most frequently
mutated gene among those involved in epigenetic reg-
ulation. PRDM2 is frequently inactivated by mutations in
colorectal cancer cell lines and in relapsed bladder can-
cer25,26. The amino-acid changing mutations we
observed, occurring in the coiled-coil domain of the
protein, lead most likely to an impaired function, poten-
tially resulting in tumor cell advantage. We also validate
the occurrence of mutations in other epigenetic reg-
ulators, namely members of the KMT2 family, BCOR, and
TET2.
PTPRC, encoding CD45, is recurrently mutated in T-
ALL, leading to downregulation of the protein30. Two of
three mutations we observed were located in the catalytic
protein tyrosine phosphatase domain, suggesting func-
tional consequences. CD45 negatively regulates JAK/
STAT signaling by dephosphorylation of all four JAKs50.
Therefore, mutations in PTPRC can enhance the already
constitutively activated JAK/STAT signaling in T-PLL12.
FOXP1 is a ubiquitously expressed transcription factor
and essential regulator in human CD4+ T cells32. Main
mechanisms leading to FOXP1 protein overexpression in
cancers are translocations, ampliﬁcations, or the repres-
sion of miRNAs normally downregulating FOXP1 trans-
lation51. All three replacement mutations observed in our
T-PLL cohort are located in the DNA-binding forkhead
domain, with unclear consequences. Notably, however, in
Fig. 4 SAMHD1 mRNA and protein expression in T-PLL. a mRNA expression levels (−ΔCT values) for SAMHD1 of T-PLL with mutated or deleted
SAMHD1 (affected) compared to T-PLL with wild-type SAMHD1 (unaffected). Samples with mutated or deleted SAMHD1 have a lower SAMHD1
mRNA expression. GAPDH was used as internal reference. Bars indicate mean and S.D. b. Protein expression levels of 12 T-PLL samples. Samples with
mutated SAMHD1 or losses show lower SAMHD1 protein expression compared to WT samples. β-actin served as loading control. mut mutated, WT
wild type, UPD uniparental disomy, ACTB Actin beta
Fig. 5 Lack of toxic effects of cytarabine on T-PLL cells. IC50 values
for cytarabine of 12 T-PLL samples separated into SAMHD1 affected (n
= 4) and SAMHD1 unaffected (n = 7) cases. Bars indicate mean and S.
D.
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other T-cell lymphoproliferative disorders FOXP1
expression is constitutionally repressed32. Clearly, the role
of FOXP1 alterations in T-PLL requires further
investigations.
Novel recurrently mutated genes identiﬁed by WES
included the ryanodine receptor 3 gene RYR3, PARN,
coding for a poly(A)-speciﬁc ribonuclease and PCLO,
encoding the piccolo presynaptic cytomatrix protein.
RYR3 releases calcium from the endoplasmic reticulum.
Intracellular calcium homeostasis plays an important role
in cell metabolism, therefore a disturbed calcium meta-
bolism caused by mutations in RYR3 or overexpression of
RYR3 may be oncogenic, as reported for several cancers52.
As the point mutations we observed are not located in
already described domains, their impact is unclear.
However, the observation of a fourfold higher expression
of the RYR3 gene in T-PLL compared to normal CD3+
T cells (p= 0.026) is in line with altered RYR3 expression
in several cancer types52. PARN was already described as a
potential tumor-suppressor gene53. Two missense muta-
tions are located directly in front and behind a coiled-coil
region of PARN, which may alter its function. PCLO is
recurrently mutated or targeted by copy number gains in
diffuse large B-cell lymphomas19,20. We identiﬁed one
missense and one frameshift mutation, and two copy
number gains in two further patients. These seemingly
contradictory ﬁndings (inactivating frameshift mutation
vs. increased gene dosage by copy gain) warrant further
investigations.
In conclusion, we identiﬁed novel recurrently mutated
genes in T-PLL, including PTPRC, regulating the JAK/
STAT pathway, epigenetic regulators like PRDM2 and
HERC1/2, and genes involved in DNA damage response
and DNA repair like SAMHD1, which has most likely a
tumor-suppressor function in T-PLL.
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